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Abstract
Background: Population-level associations between community measures of HIV viral
load and HIV incidence have been interpreted as evidence for HIV anti-retroviral treatment
(ART) as prevention among people who inject drugs (PWID). However, investigation of
concurrent HCV and HIV incidence trends allows examination of alternative explanations
for the fall in HIV incidence. We estimate the contribution of ART and reductions in inject-
ing risk for reducing HIV incidence in Vancouver between 1996 and 2007.
Methods: A deterministic model of HIV and HCV transmission among PWID was cali-
brated to the baseline (1996) HIV and HCV epidemic among PWID in Vancouver. While
incorporating parameter uncertainty, the model projected what levels of ART protection
and decreases in injecting risk could reproduce the observed reduction in HIV and HCV
incidence for 1996–2007, and so what impact would have been achieved with just ART or
just reductions in injecting risk.
Results: Model predictions suggest the estimated reduction (84%) in HCV incidence for
1996–2007 required a 59% (2.5–97.5 percentile range 49–76%) reduction in injecting risk,
which accounted for nine-tenths of the observed decrease in HIV incidence; the remain-
der was achieved with a moderate ART efficacy for reducing sexual HIV infectivity (70%,
51–89%) and an uncertain ART efficacy for reducing injection-related HIV infectivity (44%,
0–96%). Despite this uncertainty, projections suggest that the decrease in injecting risk
reduced HIV incidence by 76% (63–85%) and ART further reduced HIV incidence by 8%
(2–19%), or on its own by 3% (34–37%).
Conclusions: Observed declines in HIV incidence in Vancouver between 1996 and 2007
should be seen as a success for intensive harm reduction, whereas ART probably played
a small role.
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Introduction
The pivotal trial, HPTN 052, and numerous observational
studies among sero-discordant couples have shown that
HIV anti-retroviral treatment (ART) can reduce the risk of
heterosexual HIV transmission by over 90%,1,2 with new
evidence also suggesting prevention benefit among men
who have sex with men (MSM).3 However, although some
prevention benefit should be expected among people who
inject drugs (PWID), due to decreases in viral load, the
magnitude of this benefit is uncertain.
In a prospective cohort study conducted in Vancouver,
associations between HIV incidence among PWID and
community measures of the median HIV viral load among
diagnosed PWID (so-called community viral load) have
been interpreted as evidence for the prevention benefit of
ART among PWID.4 However, although the association
held after adjustment for time-varying injecting risk behav-
iours, which also generally decreased over the study
period, it is unclear whether all factors affecting HIV
incidence were adequately accounted for.5,6 Also, there is
discussion over whether the median viral load among
HIV-diagnosed PWID well proxies the overall infectivity
of a PWID population,7 first because it does not account
for the variability in viral load,7 and so infectivity, among
unsuppressed PWID who were the majority of HIV-
diagnosed PWID in Vancouver during the late 90 s,4 and
second because undiagnosed PWID are not incorporated in
the community viral load measure, but may contribute dis-
proportionately to transmission if many PWID are undiag-
nosed (as was case in late 90 s in Vancouver8).
Hepatitis C (HCV) is a blood-borne virus transmitted
primarily through parenteral exposure, and much less ef-
fectively by sexual exposure.9 In the Vancouver study,4 de-
clines in HCV incidence10–12 occurred concurrently with
observed decreases in HIV incidence (Figure 1). These de-
creases in HCV incidence are likely to indicate reductions
in injecting risk, which would also impact on HIV trans-
mission. We use a joint HIV and HCV transmission model
among PWID to estimate the degree to which HIV
treatment contributed to the observed decline in HIV inci-
dence in Vancouver between 1996 and 2007, as considered
by Wood et al.,4 or alternatively how much was due to re-
ductions in injecting risk. We do not consider more recent
years because our primary aim was to consider possible
reasons for the large decrease in HIV incidence previously
suggested to be due to ART scale-up.
Methods
Model description
We developed a deterministic mathematical model to simu-
late the transmission of HIV and HCV among PWID. The
model incorporates the transmission of HIV and HCV due
to injecting drug use and HIV transmission due to sexual
risk behaviour (Figure 2; further details in supplementary
material, available as Supplementary data at IJE online).
HCV transmission was not assumed to be sexually trans-
mitted because sexual HCV transmission is rare9,13 unless
linked to riskier sex acts among MSM.14 The PWID popu-
lation is divided into 10 classes depending on HIV (suscep-
tible, acute, latent, ART, lost to follow-up from ART) and
HCV (susceptible, chronic infection) infection status, and
by whether the PWID have low or high injecting risk. The
model is open, with new PWID entering through initiation
of injecting drug use, and leaving due to HIV death, non-
HIV death or cessation of injection. Although HCV infec-
tion causes excess mortality,15,16 which is elevated by HIV
co-infection17,18 and partially reversed by ART,17 HCV-
related mortality was not included because data from
Vancouver19 suggest that it contributes little to mortality
(6.0% of deaths among HCV-infected PWID: see supple
mentary materials, available as Supplementary data at IJE
online). Lastly, data are conflicting on whether HCV
affects HIV disease progression20 or response to ART,20–25
and so this was not included in our model.
The model assumes that the rate at which PWID be-
come infected with HIV or HCV is proportional to the
prevalence of that infection, which can change over time
Key Messages
• Existing evidence for the prevention benefit of ART among people who inject drugs (PWID) is based on observed
temporal associations between community measures of decreasing HIV viral load and decreasing HIV incidence in
Vancouver and Baltimore.
• Through examination of concurrent declines in HCV incidence in Vancouver, our modelling suggests that reductions
in injecting risk may have been the main reason for the observed declines in HIV incidence among PWID, with ART
playing a smaller role.
• Further evidence for the potential prevention benefit of ART among PWID is urgently needed.
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through the effect of interventions. Because of a lack of
strong evidence, ART is not assumed to reduce HCV in-
fectivity26 or the susceptibility of HIV-infected PWID to
acquiring HCV infection.14,27–31 A proportion of the base-
line HIV transmission risk is assumed to be sexually trans-
mitted, which is unaffected by decreases in injecting risk
and so increases in importance as injecting risk decreases.
Individuals in the HIV latent state can be recruited onto
ART and experience reduced HIV-related mortality unless
they are lost to follow-up.32 For PWID on ART, the rela-
tive reduction in the injecting and sexual HIV infectivity
for the period 1996–2007 is denoted by factors a2 and a3,
respectively, compared with the HIV latent phase-defined
as the efficacy of ART for reducing sexual and injecting
HIV infectivity. The relative decrease in the overall HIV
and HCV injecting transmission risk over the period 1996–
2007 is denoted by c, with c ¼ 0 denoting no change in
baseline (1996) levels of injecting risk and c ¼ 1 denoting
a 100% reduction in injecting risk.
Model parameterization
All model parameters were obtained from the literature,
with most being specific to Vancouver (Table 1). Uniform
uncertainty bounds were assigned to all model parameters
except for: (i) the baseline HIV transmission rate during
the latent stage of HIV (b) and the factor difference be-
tween the baseline HIV (during HIV latent stage) and
HCV transmission rate (w); and (ii) the efficacy of ART in
reducing a PWID’s injection-related HIV infectivity (a2),
and the factor decrease in HIV and HCV injecting trans-
mission risk (c), which were all varied widely in the model
fitting process. More details are included in the model cali-
bration section.
To be conservative, ART was assumed to decrease sex-
ual HIV transmission (a3) by 50–90%,
2 with the lower
bound based on the proportion of PWIDs on ART who
were virally suppressed in Vancouver at this time.33 This
variable was varied more widely in the initial exploratory
analysis. The ART recruitment rate (x) was calibrated
such that the proportion of HIV-infected PWID on highly
effective ART (HAART) was negligible in 1996,34,35 then
increased up to 40% by 2000 and remained stable at that
level till 2007,35 roughly similar to the real trends which
increased rapidly to about 34% coverage by 1999, and
then slowly increased to 40% by 2006.36,37 Coinciding
with increases in Opioid substitution therapy coverage12
and decreases in syringe sharing,12,38 injecting risk was
assumed to decrease exponentially over this period to a
calibrated stable level (see supplementary materials, avail-
able as Supplementary data at IJE online).
More details on the model parameters are included in
the supplementary materials and Table 1. The proportion
of the baseline HIV transmission rate due to sexual risk
(s¼ 10% (5–25%)) was based on the population-
attributable fraction (6.4%, minimum to maximum range
1.0–18.5%39 – see supplementary materials, available as
Supplementary data at IJE online) for the only sexual risk
factor shown to be associated with incident HIV sero-
conversion among Vancouver PWID (having a HIV-
positive sexual partner39) over this time period. The range
was widened to allow for unobserved sexual risk factors
that may have been important for HIV transmission in
this setting, and to ensure that the importance of sexual
HIV transmission was not underestimated. Importantly,
no other ‘high-risk’ sexual behaviours, such as a man hav-
ing sex with another man,40 commercial sex,39–46
having> 20 lifetime sexual partners46,47 or unprotected/
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Figure 1. HIV incidence and HCV incidence data among at risk susceptible PWID in Vancouver from 1996 to 2007. Data from Wood et al. (2009)4 and
Grebely et al. (2014)10.
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unsafe sex,4,38–46,48,49 were related to incident HIV sero-
conversion in adjusted analyses over this time in
Vancouver; whereas many injection-related risk factors
were consistently and strongly related, such as daily co-
caine/speedball injecting,4,38–44,47–51 requiring help in-
jecting,39,40,42,44,49,51 binge drug use39,41,44,50 and
borrowing needles.40,43,48,50,51 This gives a highly con-
sistent picture that injecting risk behaviours were the
main drivers of HIV transmission over this time period,
with sexual HIV transmission probably playing a small
role, and so our assumption is unlikely to underestimate
the importance of sexual HIV transmission.
Baseline (1996) HIV and HCV prevalence11 and inci-
dence4,12 estimates were obtained from the Vancouver
Injection Drug Users Study (VIDUS). HCV and HIV anti-
body prevalence (82% and 21%,11 respectively) came
from PWID recruited between 1996 and 1999. As approxi-
mately 26% of individuals spontaneously clear acute
Figure 2. Model schematic showing the HCV and HIV infection states and transitions. Variables are denoted by capital letters for the HIV infection
states (X,H,Y,T and L representing susceptible, acute, latent, ART and ART lost to follow-up, respectively) and the lower-case letters for HCV infec-
tion states (x, y representing susceptible and chronic infection, respectively). Arrows show possible transitions from one state to the other and are
labelled by the flow rates. New PWID enter the population at a rate U and leave all compartments due to non-HIV death (rate l) or cessation of in-
jection (rate ). Forces of infection for HIV and HCV are P and p, respectively. For HIV transmission, PWID infected with HIV enter the acute stage
(with average duration of 1/ n) and then progress to the latent stage. Latently infected HIV individuals experience HIV-related death at a rate u and
are also recruited onto anti-retroviral treatment (ART) at a rate x. For those on ART, HIV-related death is reduced by a factor k, but some individuals
are permanently lost to follow-up from ART at rate f. For HCV transmission, a proportion of those infected with HCV spontaneously clear infection
and the remaining proportion progress to chronic infection (proportion d for those uninfected with HIV, reduced by a factor r for those co-infected
with HIV).
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Table 1. Parameter values and uncertainty ranges (all uniformly sampled) used in numerical simulations
Parameter definition and (symbol) Range or
value used
Data source
HIV biological parameters:
HIV transmission probability in the latent stage (b) Varied freely Varied to fit HIV prevalence in 1997
Cofactor difference in HIV transmission rate in HIV acute
stage compared with latent HIV stage (a1)
3–25 71
Duration of acute HIV stage in years (1=n) 1/12–0.25 71
HIV mortality rate per year during latent HIV stage (u) 1/10 72–74
HCV biological parameters:
Factor difference between HCV and HIV transmission rate
for the HIV latent stage (w)
4–10 Varied to fit HCV prevalence in 1997
Relative HCV transmissibility if HIV co-infected (h) 1–7 Reviewed75
Proportion of HCV infections that spontaneously clear (d) 0.22–0.29 52
Relative risk of spontaneous clearance if HIV co-infected (r) 0.21–0.58 Reviewed75
PWID behavioural and demographic parameters:
PWID Recruitment rate (U) Recalibrated for
each run
Varied to balance non-HIV exit rates
Injecting cessation rate per year () 1/23–1/7 76
Non-HIV mortality rate per year (l) 1.5–2.0% 12
Proportion of baseline HIV transmission risk due to sexual
HIV transmission (s)
10% (5–25%) Derived based on the population-attributable fraction
[6.4% (1.0–18.5%)39] for only sexual risk factor con-
sistently associated with HIV sero-conversion among
PWID in VIDUS between 1996 and 2003 (having an
HIV-positive sexual partner39)
Proportion of the PWID population that are high-risk (M) 0.3–0.6 Similar to the proportion of PWID in unstable housing
or crack/heroin injecting in Vancouver in 199612,62
Factor difference in HIV and HCV injecting transmission
risk among high-risk PWID compared with low-risk
PWID (m)
1–4.8 Based on the enhanced HIV or HCV transmission risk
associated with daily cocaine or heroin injecting or
unstable housing in the VIDUS cohort4,10,11,62
Duration that PWID remain high-risk in years (1=c) 3.2 (1.6–4.8) 12
Degree to which PWID mix proportionately or assorta-
tively (like-with-like) with PWID of the same injecting
risk (e)
0–0.6 No data, so allowed proportionate ‘random’ mixing
(e ¼ 0) as well as up to double the level of assorta-
tive mixing (e>0 but up to 0.6) found among PWIDs
in UK77
ART and changes in injecting risk parameters
Relative decrease in HIV and HCV transmission risk due to
decreases in injecting risk (c)
0–1 Set to zero for initial fitting to 1996 data, then varied to
fit to decrease in HCV incidence over 10 years from
1996 to 2007. Assumed to increase to stable level,
similar to recent trends in OST coverage and de-
creases in syringe-sharing in Vancouver12,38
Rate of recruitment on to ART per year (x)  0 Set to zero for initial model fitting in 1996, and then
varied to fit to ART coverage trends in Vancouver35
Rate of permanent loss to follow-up from ART per year (f) 15% (10.5–
19.5%)
Data from Nosyk AIDS 201532 used to estimate the rate
of permanent loss to follow up from ART for PWID
Relative decrease in parenteral HIV transmission rate while
on ART compared with latent HIV stage (a2)
0–0.95 Trials suggest>90% reduction for sero-discordant cou-
ples1 but no data for PWID or parenteral HIV trans-
mission and recent observational data suggest efficacy
among couples could be much lower in real life2
Relative decrease in sexual HIV transmission rate while on
ART compared with latent HIV stage (a3)
0.5–0.9 Range obtained from meta-analysis of trials and obser-
vational studies undertaken among sero-discordant
couples1,2 with lower bound based on the proportion
of PWIDs virally suppressed after 1 year of ART in
Vancouver33
(continued)
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HCV infection,52 a baseline HCV chronic prevalence of
61% was assumed. Because of uncertainty and yearly fluc-
tuations in incidence estimates (measured among those at
risk), negative exponential curves (with non-zero asymp-
totes) were fit to the incidence data for 1996–20074,10
using the nonlinear least squares method. This suggested
that HIV and HCV incidence decreased by 84% (95% con-
fidence interval (CI) 76–86%) and 84% (95% CI 78–
93%), respectively, over the decade (Figure 3).
Model calibration
The HIV and HCV prevalence at baseline and HIV and
HCV incidence in 2007 (estimated from the curve fits),
and all model parameters with uncertainty distributions in
Table 1, were randomly sampled to give 5000 model par-
ameter sets. For each parameter set, the HIV transmission
rate (b) and factor difference between the HIV and HCV
transmission probabilities (w) were first varied to fit the
model’s endemic HIV and HCV prevalence to the sampled
baseline HIV and HCV prevalence among PWID in 1996.
This was done using the Matlab function lsqnonlin to min-
imize the squared error. A parameter set was accepted as a
‘baseline model fit’ if it also gave an HIV and HCV inci-
dence within the uncertainty range of the baseline HIV and
HCV incidence data for 1996.
These baseline model fits were then used to determine
what combinations of ART efficacy for reducing injection-
related HIV infectivity (a2) and decreases in injecting
risk (c) could result in the sampled HIV and HCV inci-
dence after 10 years in 2007 (using the same Matlab nu-
merical routine), with runs being rejected if the decrease in
injecting risk needed to achieve the sampled decrease in
HCV incidence resulted in a decrease in HIV incidence
larger than observed. This produced 902 ‘full model fits’.
Further details of the model calibration are in the supple
mentary material, available as Supplementary data at IJE
online.
Model analyses
To understand the contribution of ART and changes in in-
jecting risk to decreasing HIV and HCV incidence, the 902
full model fits were used to project the decrease in HIV
and HCV incidence that would occur over 10 years with
varying efficacies of ART for reducing sexual and
injection-related HIV infectivity (a2and a3¼ 0, 30%, 60%
and 90%) and/or different relative decreases in injecting
risk (c¼ 0, 30%, 60% and 90%).
The 902 full model fits were then used to estimate the
likely contribution that ART or changes in injecting risk
made to the observed reduction in HIV incidence among
PWID for 1996–2007. The proportion of the modelled de-
crease in HIV incidence that would have occurred with just
the effect of ART on HIV transmission being included (c
set to zero across all full model fits), or without the preven-
tion effect of ART being included (a2 and a3 set to zero
across all full model fits) was estimated.
Table 1. Continued
Parameter definition and (symbol) Range or
value used
Data source
Cofactor difference in HIV mortality rate while on ART
compared with latent HIV stage (k)
1/6–1/2 Estimate for Vancouver from 1996 to 2007,78 but
allow uncertainty.79 Does not affect model projec-
tions because only modelling duration of current
injecting
HIV and HCV epidemiological data used to calibrate the model:
HIV prevalence at baseline in 1996 21%
(19.2–23.7%)
HIV prevalence among PWID recruited into VIDUS be-
tween 1996 and 199911
HIV incidence per 100 person years at baseline in 1996 6.3
(95% CI 3.3–9.3)
Exponential curve fitting to HIV incidence data from
Wood et al.4
Chronic HCV prevalence at baseline in 1996 61%
(58.9–61.9%)
HCV antibody prevalence among PWID (81.6%) re-
cruited into VIDUS between 1996 and 199911
scaled down by 26% due to spontaneous
clearance52
HCV incidence per 100 person years at baseline in 1996 41.2 (95% CI
33.7–48.7)
Exponential curve fitting to HCV incidence data from
Grebely et al.10
Percentage decrease in HIV incidence over 1996–2007 84% (95% CI 76–
86%)
Exponential curve fitting to HIV incidence data from
Wood et al.4
Percentage decrease in HCV incidence over 1996–2007 84% (95% CI 78–
93%)
Exponential curve fitting to HCV incidence data from
Grebely et al.10.
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Last, a linear regression analysis of covariance
(ANCOVA) was undertaken53 on the range of model pro-
jections for the contribution of ART to decreasing HIV in-
cidence for all 902 full model fits. This analysis estimated
the proportion of the variability in the model projections
(proportion of the sum of squares) that could be attributed
to uncertainty in different model parameters or inputs. A
linear regression model was then developed; including the
most important parameters from the ANCOVA analysis,
to determine across what parameter region the model-
predicted ART made a noticeable contribution ( 20%
decrease in HIV incidence).
Ethics
Patient consent was not needed because no patients were
involved in the study. Ethics committee approval was not
needed because the study used previously published sec-
ondary data
Results
Impact of injecting risk and ART on HIV and HCV
incidence
Figure 4 shows, for different reductions in injecting risk ðcÞ
and ART efficacy for decreasing HIV infectivityða2 and a3Þ,
the projected decrease in HIV and HCV incidence for 1996–
2007 among PWID in Vancouver. Both high ART efficacy
( 90%) or moderate decreases in injecting risk ( 30%)
could have resulted in noticeable decreases in HIV inci-
dence, whereas only reductions in injecting risk would have
decreased HCV incidence. However, increases in HIV inci-
dence could have occurred with just ART if there had been
low to moderate ART efficacy (a2 and a3 < 50%), due to
improvements in HIV survival with ART. Also ART is un-
likely to have decreased HIV incidence by over 40% even
with high ART efficacy (90%) due to the moderate coverage
of ART over this period ( 40%).
Contribution of ART and reductions in injecting
risk to reducing HIV incidence in Vancouver
The model closely fitted the HCV and HIV incidence
trends (Figure 3) except for the high HIV incidence in
1997. This high HIV incidence should be considered an
outlier, probably due to an HIV outbreak,11 because it is
3-fold higher than any other time period.
To achieve the observed decrease in HCV incidence for
1996–2007, a large decrease in injecting risk (median
of 59%, 2.5 to 97.5 percentile range 49–76%) must have
occurred. This resulted in a median 76% (63–85%)
decrease in HIV incidence among PWID (Figure 5), contri-
buting nine-tenths (90%, 77–98%) of the overall reduction
in HIV incidence achieved from 1996 to 2007.38 Once this
reduction in injecting risk had been accounted for, the full
observed reduction in HIV incidence was achieved with a
moderate efficacy of ART for reducing sexual HIV infect-
ivity (70%, 51–89%) and an uncertain efficacy for reduc-
ing injection-related HIV infectivity (44%, 0–96%).
Model projections suggest that the scale-up of ART
alone (Figure 5) would have at best resulted in a 37% (3%,
-34–37%) decrease in HIV incidence, with an 86% chance
that the decrease was< 25%, whereas its incremental im-
pact on top of what was achieved through decreasing in-
jecting risk was a median 8% (2–19%) decrease in HIV
incidence. Uncertainty in the beneficial impact of ART
alone results partly from HIV incidence increasing between
1996 and 2007 if ART has low efficacy (as shown in
Figure 3. Curve fits to temporal trends in HIV and HCV incidence data
among at-risk susceptible PWID in the Vancouver VIDUS cohort, with
model fits shown for comparison. Solid circles show HIV (a) or HCV (b)
incidence data, whereas the grey line shows the curve fit to these data
using non-linear least squares method, and dashed grey lines are the
95% confidence intervals. The squares are the median with whiskers rep-
resenting 2.5 and 97.5% percentiles from the model fits; yrs, years.
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Figure 4), with the ART efficacy needing to be> 50% to
result in HIV incidence decreasing.
Sensitivity analyses
In ANCOVA analyses, most (< 95%) of the variability
in the projected overall contribution of ART for decreas-
ing HIV incidence in Vancouver was due to uncertainty
in both the level of sexual HIV transmission (s – contrib-
utes 19% to the variability) and the assumed decrease in
HIV and HCV incidence between 1996 and 2007 (con-
tributes 28% and 51%, respectively). The effect of all
other model parameters was small (Supplementary
Figure 1, available as Supplementary data at IJE online).
Linear regression analyses also suggested that ART alone
would only have achieved moderate impact ( 20% de-
crease in HIV incidence) if the observed decreases in
HIV and HCV incidence were towards the upper (86%)
and lower (78%) bounds, respectively, of what data sug-
gested and there had been considerable sexual HIV
transmission (s¼ 25%).
Discussion
HIV treatment to prevent heterosexual HIV transmission is
well accepted at the individual level,1,2 and community
randomized trials are under way to assess its impact at the
population level.54 Although HIV treatment is also likely
to reduce parenteral HIV transmission, current evidence
for its effectiveness is limited4.
Although both modelling and observational data will
suffer from weaknesses, specifically in terms of evidence
for causation, our analyses are still useful for raising alter-
native hypotheses for why HIV incidence declined in
Figure 4. Relative decrease in HIV and HCV incidence for 1996 to 2007 for different efficacies of ART for reducing HIV infectivity (a2 and a3), and reduc-
tions in injecting risk (c). All projections assume a scale-up to 40% ART coverage among HIV-infected PWID by 2006 and assume that ART reduces
HIV morbidity even when ART is assumed to have no effect on HIV transmission. The box plots signify the uncertainty (middle line is median, limits
of boxes are 25% and 75% percentiles, and whiskers are 2.5% and 97.5% percentiles) in the impact projections due to uncertainty in the model
parameters.
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Vancouver. In contrast to earlier studies, our evaluation
suggests large decreases in injecting risk dramatically
reduced HIV incidence in Vancouver between 1996 and
2007, with the scale-up of HIV treatment over that period
playing a smaller role.4 The current analysis addresses con-
cerns voiced by other researchers.5,6 Without question,
scale-up of ART occurred35 and this scale-up probably
contributed to a decline in ‘community viral load’.4,55
However, the concurrent decline in HCV incidence10,12
observed during the scale-up of ART indicates that inject-
ing risks also decreased,10,38 and contributed to the de-
crease in HIV incidence. Indeed, our model projections
suggest that the reductions in injecting risk required to re-
produce the observed declines in HCV incidence probably
accounted for most ( 90%) of the observed decline in
HIV incidence. These projections are consistent with ART
only contributing an additional 8% (2–19%) decrease in
HIV incidence on top of reduced injecting risk. Although
uncertain, possible reasons for this small contribution of
ART could be the moderate ART coverage ( 40% of
HIV-infected PWID) and low proportion of HIV-infected
PWID that were virally suppressed (less than 28%) over
this period.4,36,55
Limitations
As with all modelling studies, this analysis has limitations.
First, we cannot reject the possibility that the decreases in
HIV and HCV incidence were partly due to a closed cohort
effect, where the observed HIV and HCV incidence in a co-
hort tends to decrease over time because the highest-risk
PWIDs become infected first with high HIV/HCV inci-
dence risk, followed by successively lower-risk PWID with
decreasing HIV/HCV incidence risk.56 However, this
should not be a concern because the Vancouver PWID co-
hort was an open cohort,11 and data from other more re-
cent cohorts in Vancouver (ARYS) suggest similar HCV
incidence rates among PWID (6.5 per 100 person-years)
and very little HIV transmission.57 Also, one could hy-
pothesize that HCV incidence decreased due to the epi-
demic saturating or peaking at high prevalence, rather than
due to decreases in injecting risk. However, this was not
considered the main effect in a recent analysis evaluating
the decreases in HCV incidence in Vancouver since
1996.10 This is supported by data showing HCV incidence
remained high till 2000 (> 15 per 100 person-years) des-
pite there being high HCV sero-prevalence (82%),10,11 and
as Figure 1 shows, the decreases in HCV incidence fol-
lowed HIV incidence trends suggesting that common fac-
tors affected both infections, which coincided with large
reductions in injecting risk and increases in intervention
coverage.10,12,38
Second, uncertainty in the HIV and HCV incidence
data made it hard to determine the precise reductions in in-
cidence. Uncertainty in many model parameters also ham-
pered the analysis. To counter these uncertainties, smooth
curves were fit to the incidence trends, and our modelling
incorporated the uncertainty in these incidence trends as
well as the model parameters, and were consistent despite
this.
Third, we modelled sexual HIV transmission simply,
which we feel is warranted because evidence suggests that
it played a small role over this period (see Methods).
Further, we assumed the observed decrease in HIV inci-
dence was solely due to decreases in injecting risk and the
prevention effect of ART, whereas decreases in sexual HIV
risk behaviour may have also contributed. If decreases in
sexual risk occurred, our ART impact projections would
be optimistic and so should not affect our conclusion of a
limited effect of ART. We also assumed there was negli-
gible sexual HCV transmission, which is rare9,13 unless
associated with anal sex,14,27 This behaviour was reported
by less than 10% of PWID in Vancouver,58,59 and even
among MSM much lower HCV incidence rates normally
occur than among PWID.27,60
Fourth, our modelling did not attempt to explicitly at-
tribute the decline in injecting risk to specific interventions,
although our modelled decline (60%) was consistent with
observed reductions in syringe sharing.38 However, a num-
ber of important determinants of injecting risk changed
concurrently with the declines in HIV/HCV incidence, and
Figure 5. Model projections of the degree to which ART on its own (dark
grey box), just reductions in injecting risk (light grey box), or both com-
bined (white box) decrease HIV incidence among PWID in Vancouver
over the period 1996 to 2007. Note: we still assume that ART reduces HIV
morbidity in all model projections even when ART is assumed to have no
effect on HIV transmission. The curve fit estimated decrease in HIV inci-
dence is shown for comparison (point and whisker on left).
474 International Journal of Epidemiology, 2017, Vol. 46, No. 2
so could account for our predicted decrease in injecting
risk. These include OST scaling-up from about 12% to
40% of PWID,12 changes in syringe exchange programme
policy,38 recent incarceration decreasing from 35% to
15% of PWID in the past 6 months and unstable housing12
decreasing from 63% to 50% of PWID, all of which have
been shown to be associated with decreased individual
HIV and HCV acquisition risk in Vancouver,10,38,43,61–63
Subsequent analyses should evaluate the potential popula-
tion impact of these intervention and structural changes.
Fifth, because of a lack of evidence we assumed that
ART does not affect HCV infectivity. This could be a con-
servative assumption as some studies suggest HCV viral
loads are elevated among individuals on ART.26 Last, we
did not consider the impact of ART in Vancouver for more
recent years8,36,37 because this was not the primary aim of
our analysis. It is likely that ART has had more impact
since 2007, as has been considered in other recent model-
ling,64 because the coverage of ART, retention and viral
suppression are now much higher.8,36,37
Other evidence
The impact of HIV treatment as prevention among PWIDs
has been considered in other modelling analyses,65–69
including Vancouver64. Despite limited evidence, these
analyses a priori assumed that ART had moderate to high
efficacy for preventing parenteral HIV transmission.64
Through modelling competing hypotheses for why HIV in-
cidence decreased in Vancouver, we estimate the potential
effectiveness of treatment as prevention among PWID in a
specific setting, and test the robustness of findings from
earlier analyses.
Conclusions
Reducing HIV and HCV transmission among PWID re-
mains a critical goal. The considerable (> 75%) reductions
in HCV and HIV incidence that occurred among PWID in
Vancouver represents a remarkable success for intensive
harm reduction interventions. Although ART is undoubt-
edly important for reducing HIV morbidity and mortal-
ity,70 our analyses suggest that it may not have
substantially reduced HIV transmission among PWID in
Vancouver over this period. As with all modelling, our
analysis cannot replace empirical evidence, but the insights
obtained do give alternative hypotheses for why HIV inci-
dence declined. This does not diminish the potential for
HIV treatment as prevention among PWID, but rather sug-
gests that further studies are needed to determine its
benefits.54
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